PLC
ORMP icon

Peapod Lane Capital’s Oramed Pharmaceuticals ORMP Stock Holding History

Peapod Lane Capital’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-84,779
Closed -$191K – 60
2025
Q2 		$191K Sell
84,779
-167,445
-66% -$369K 0.19% 57
2025
Q1 		$540K Buy
252,224
+24,985
+11% +$57.6K 0.61% 51
2024
Q4 		$550K Buy
+227,239
New +$540K 0.55% 53

Other funds holding ORMP

BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
AF
Aquamarine Financial George Town $1.81B AUM 38.21% 1-Year Est. Return
M
Murchinson Toronto, Ontario, Canada $725M AUM 82.02% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Peapod Lane Capital's ORMP Position: Q3 2025 in Review

Peapod Lane Capital sold out of Oramed Pharmaceuticals (ORMP) in Q3 2025, closing a stake of 84,779 shares — an estimated $191K sold.

Peapod Lane Capital first reported a position in ORMP in Q4 2024 and held it in 3 quarters. The position peaked at $550K in Q4 2024. 47 funds tracked by Wall St. Rank hold ORMP as of Q3 2025.

  • Peapod Lane Capital reported no remaining Oramed Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Peapod Lane Capital sold 84,779 Oramed Pharmaceuticals shares in Q3 2025, an estimated $191K.
  • Peapod Lane Capital first reported a position in Oramed Pharmaceuticals in Q4 2024 and held it in 3 quarters.
  • Peapod Lane Capital's Oramed Pharmaceuticals position peaked at $550K in Q4 2024.
  • 47 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q3 2025.

Based on Peapod Lane Capital's 13F filing for Q3 2025, filed 10 Nov 2025.